MARKET

VRNA

VRNA

Verona Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.500
0.000
0.00%
Closed 16:00 09/13 EDT
OPEN
4.680
PREV CLOSE
4.360
HIGH
4.680
LOW
4.500
VOLUME
25
TURNOVER
--
52 WEEK HIGH
14.50
52 WEEK LOW
3.650
MARKET CAP
58.95M
P/E (TTM)
-2.3828
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of VRNA and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

VRNA News

  • Holding(s) in Company TR-1: Standard form for notification of major holdings
  • GlobeNewswire.6d ago
  • Verona Pharma to Present at H.C. Wainwright 21st Annual Global Investment Conference
  • GlobeNewswire.09/03 07:00
  • Verona Pharma plc (VRNA) CEO Jan-Anders Karlsson on Q2 2019 Results - Earnings Call Transcript
  • Seeking Alpha - Transcript.08/10 23:19
  • Verona Pharma plc: PDMR Dealing
  • GlobeNewswire.08/09 09:35

More

Industry

Biotechnology & Medical Research
+0.20%
Pharmaceuticals & Medical Research
-0.38%

Hot Stocks

Name
Price
%Change

About VRNA

Verona Pharma plc is a United Kingdom-based clinical-stage biopharmaceutical company. The principal activity of the Company is the development of drugs for the treatment of chronic respiratory diseases, such as chronic obstructive pulmonary disease (COPD), asthma and cystic fibrosis. The Company's product candidate, RPL554, is a dual inhibitor of the enzymes phosphodiesterase 3 and 4 (PDE3 and PDE4) that acts as both a bronchodilator and an anti-inflammatory agent in a single compound. The Company is developing RPL554 in a nebulized formulation for the maintenance treatment of COPD patients and for the treatment of cystic fibrosis. It also is developing RPL554 as an add-on therapy to commonly used therapies for the treatment of acute exacerbations of COPD in the hospital setting. In addition to its nebulized formulation of RPL554, the Company is developing RPL554 in both dry powder inhaler (DPI) and metered dose inhaler (MDI) formulations for the maintenance treatment of COPD.
More

Webull offers Verona Pharma Plc (VRNA) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.